Document is current
Any future updates will be listed below
-
Authors
Keuss, Sarah E.
Lu, Kirsty
James, Sarah-Naomi
Nicholas, Jennifer M.
Coath, William
Keshavan, Ashvini
Cash, David M.
Sudre, Carole H.
Barnes, Josephine
Murray-Smith, Heidi
Wong, Andrew
Street, Rebecca
Richards, Marcus
Schott, Jonathan M.
-
Funding
Funding for this research was provided by:
Alzheimer's Association (SG-666374-UK BIRTH COHORT)
National Institute for Health Research for DIADEM (NIHR204280)
Alzheimer’s Research UK (ARUK-BBC2023-002)
UK Dementia Research Institute
UK Research and Innovation (MR/V03863X/1)
National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre
- License Information
-
More Information
Article History
Received: 4 December 2024
Accepted: 11 June 2025
First Online: 22 January 2026
Declarations
:
: Ethical approval was granted by the National Research Ethics Service (NRES) Committee London (14/LO/1173). All participants provided written informed consent to participate.
: Not applicable.
: AK is an executive member of the Biofluid Biomarkers Professional Interest Area of the Alzheimer’s Association (unpaid). DMC is the chair of the Neuroimaging Professional Interest Area of the Alzheimer’s Association (unpaid). JMS has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly) and Alliance Medical; has consulted for Roche, Eli Lilly, Biogen, AVID, Merck and GE; and received royalties from Oxford University Press and Henry Stewart Talks. He is Chief Medical Officer for Alzheimer’s Research UK. CHS is a scientific advisor to Brainkey. SK received honoraria for educational content for M3 (which was sponsored by Eli Lilly).
